Kif14

A clinically relevant kinesin and potential target for cancer therapy

Brigitte L. Thériault, Timothy Corson

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Kinesin family member 14 (KIF14) is an atypical N-3 kinesin identified as a potential oncogene in the prototypic genetic cancer retinoblastoma. KIF14 is crucial for the last phases of cytokinesis, where it interacts with protein regulating cytokinesis 1 (PRC1), citron kinase (CIT) and supervillin to mediate formation of the cleavage furrow. However its importance in cancer is perhaps better characterized than its cell biology, and has generated much interest in this kinesin as a potential prognostic marker and exciting therapeutic target. Located on chromosome 1q32.1, a common region of gain in many cancers, KIF14 demonstrates genomic gain and overexpression in multiple neoplasms. KIF14 expression is tumor-specific, and in breast, lung, ovarian, liver, and brain cancers expression correlates with stage, aggressiveness and poor patient outcomes. In cancer cells, KIF14 interacts with tumorigenic signaling pathways that promote cellular behaviors such as adhesion, invasion and chemotherapeutic resistance, with the end result of promoting tumor progression. Here we discuss the mounting evidence pointing to KIF14 as a prognostic marker and oncogenic stimulus in multiple cancers, as well as the additional evidence required for validation of KIF14 as a potential drug target.

Original languageEnglish
Title of host publicationKinesins and Cancer
PublisherSense Publishers
Pages149-170
Number of pages22
ISBN (Print)9789401797320, 9789401797313
DOIs
StatePublished - Jan 1 2015

Fingerprint

Kinesin
Neoplasms
Cytokinesis
Therapeutics
Tumors
Cytology
Retinoblastoma
Liver Neoplasms
Chromosomes
Mountings
Oncogenes
Brain Neoplasms
Liver
Ovarian Neoplasms
Cell Biology
Lung Neoplasms
Brain
Adhesion
Cells
Breast Neoplasms

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Chemistry(all)

Cite this

Kif14 : A clinically relevant kinesin and potential target for cancer therapy. / Thériault, Brigitte L.; Corson, Timothy.

Kinesins and Cancer. Sense Publishers, 2015. p. 149-170.

Research output: Chapter in Book/Report/Conference proceedingChapter

Thériault, Brigitte L. ; Corson, Timothy. / Kif14 : A clinically relevant kinesin and potential target for cancer therapy. Kinesins and Cancer. Sense Publishers, 2015. pp. 149-170
@inbook{f0a63cde15ba47368a22382e9ba1e2ac,
title = "Kif14: A clinically relevant kinesin and potential target for cancer therapy",
abstract = "Kinesin family member 14 (KIF14) is an atypical N-3 kinesin identified as a potential oncogene in the prototypic genetic cancer retinoblastoma. KIF14 is crucial for the last phases of cytokinesis, where it interacts with protein regulating cytokinesis 1 (PRC1), citron kinase (CIT) and supervillin to mediate formation of the cleavage furrow. However its importance in cancer is perhaps better characterized than its cell biology, and has generated much interest in this kinesin as a potential prognostic marker and exciting therapeutic target. Located on chromosome 1q32.1, a common region of gain in many cancers, KIF14 demonstrates genomic gain and overexpression in multiple neoplasms. KIF14 expression is tumor-specific, and in breast, lung, ovarian, liver, and brain cancers expression correlates with stage, aggressiveness and poor patient outcomes. In cancer cells, KIF14 interacts with tumorigenic signaling pathways that promote cellular behaviors such as adhesion, invasion and chemotherapeutic resistance, with the end result of promoting tumor progression. Here we discuss the mounting evidence pointing to KIF14 as a prognostic marker and oncogenic stimulus in multiple cancers, as well as the additional evidence required for validation of KIF14 as a potential drug target.",
author = "Th{\'e}riault, {Brigitte L.} and Timothy Corson",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-94-017-9732-0_10",
language = "English",
isbn = "9789401797320",
pages = "149--170",
booktitle = "Kinesins and Cancer",
publisher = "Sense Publishers",

}

TY - CHAP

T1 - Kif14

T2 - A clinically relevant kinesin and potential target for cancer therapy

AU - Thériault, Brigitte L.

AU - Corson, Timothy

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Kinesin family member 14 (KIF14) is an atypical N-3 kinesin identified as a potential oncogene in the prototypic genetic cancer retinoblastoma. KIF14 is crucial for the last phases of cytokinesis, where it interacts with protein regulating cytokinesis 1 (PRC1), citron kinase (CIT) and supervillin to mediate formation of the cleavage furrow. However its importance in cancer is perhaps better characterized than its cell biology, and has generated much interest in this kinesin as a potential prognostic marker and exciting therapeutic target. Located on chromosome 1q32.1, a common region of gain in many cancers, KIF14 demonstrates genomic gain and overexpression in multiple neoplasms. KIF14 expression is tumor-specific, and in breast, lung, ovarian, liver, and brain cancers expression correlates with stage, aggressiveness and poor patient outcomes. In cancer cells, KIF14 interacts with tumorigenic signaling pathways that promote cellular behaviors such as adhesion, invasion and chemotherapeutic resistance, with the end result of promoting tumor progression. Here we discuss the mounting evidence pointing to KIF14 as a prognostic marker and oncogenic stimulus in multiple cancers, as well as the additional evidence required for validation of KIF14 as a potential drug target.

AB - Kinesin family member 14 (KIF14) is an atypical N-3 kinesin identified as a potential oncogene in the prototypic genetic cancer retinoblastoma. KIF14 is crucial for the last phases of cytokinesis, where it interacts with protein regulating cytokinesis 1 (PRC1), citron kinase (CIT) and supervillin to mediate formation of the cleavage furrow. However its importance in cancer is perhaps better characterized than its cell biology, and has generated much interest in this kinesin as a potential prognostic marker and exciting therapeutic target. Located on chromosome 1q32.1, a common region of gain in many cancers, KIF14 demonstrates genomic gain and overexpression in multiple neoplasms. KIF14 expression is tumor-specific, and in breast, lung, ovarian, liver, and brain cancers expression correlates with stage, aggressiveness and poor patient outcomes. In cancer cells, KIF14 interacts with tumorigenic signaling pathways that promote cellular behaviors such as adhesion, invasion and chemotherapeutic resistance, with the end result of promoting tumor progression. Here we discuss the mounting evidence pointing to KIF14 as a prognostic marker and oncogenic stimulus in multiple cancers, as well as the additional evidence required for validation of KIF14 as a potential drug target.

UR - http://www.scopus.com/inward/record.url?scp=84943176360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943176360&partnerID=8YFLogxK

U2 - 10.1007/978-94-017-9732-0_10

DO - 10.1007/978-94-017-9732-0_10

M3 - Chapter

SN - 9789401797320

SN - 9789401797313

SP - 149

EP - 170

BT - Kinesins and Cancer

PB - Sense Publishers

ER -